NOV 17, 202658 MINS READ
The chemical identity of Acetyl Hexapeptide-8 is defined by its precise molecular formula C₃₄H₆₀N₁₄O₁₂S, corresponding to a molecular weight of 888.91 g/mol and CAS registry number 616204-22-9 4. This hexapeptide represents a chemically modified fragment mimicking the SNAP-25 (synaptosome-associated protein of 25 kDa) N-terminus, engineered to interfere with neurotransmitter vesicle fusion mechanisms 13. The peptide sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ reveals several structurally significant features that govern its biological activity and physicochemical properties 1.
At the N-terminus, acetylation of the glutamic acid residue (Ac-Glu) enhances metabolic stability by protecting against aminopeptidase degradation, a critical modification for maintaining peptide integrity in topical formulations 13. The consecutive glutamic acid residues (Glu-Glu) contribute negative charges at physiological pH, influencing solubility behavior and electrostatic interactions with cellular membranes 4. The central methionine (Met) residue introduces a thioether functional group susceptible to oxidation, representing a key stability challenge that must be addressed through formulation strategies—related peptide impurities should not exceed 2.0%, and methionine oxidation-related peaks must remain below 0.8% for quality control 11. The glutamine (Gln) residue provides hydrogen bonding capacity, while the C-terminal arginine dipeptide (Arg-Arg-NH₂) with amidation modification enhances cell-penetrating properties through positive charge density and protects against carboxypeptidase cleavage 13.
The three-dimensional conformation adopted by Acetyl Hexapeptide-8 in aqueous solution directly impacts its ability to compete with SNAP-25 for binding sites on the SNARE complex. Structural studies indicate that the peptide maintains sufficient flexibility to adapt to the target binding pocket while retaining specificity for the synaptic vesicle fusion machinery 1. The calculated density of 1.5 ± 0.1 g/cm³ reflects the compact packing of this relatively hydrophilic peptide in solid state 4.
Key structural parameters include:
The peptide exhibits polymorphism in solid state, with multiple crystalline forms (designated as Form A, B, C, D, and E) demonstrating distinct X-ray powder diffraction patterns and differential scanning calorimetry profiles 410. Form D, for instance, displays characteristic endothermic peaks at 248.8 ± 2°C and 255.5 ± 2°C, indicating specific thermal transition behaviors 10. These crystalline forms differ significantly in their solubility profiles—while lyophilized powder shows poor solubility in 1,2-pentanediol, Form B enables preparation of oil-soluble formulations with Acetyl Hexapeptide-8 content reaching 2160 ppm 4. Forms C, D, and E demonstrate superior stability in oil-based systems compared to lyophilized powder or Form B, making them particularly suitable for lipophilic cosmetic matrices 10.
Solid-phase synthesis represents the predominant industrial approach for manufacturing Acetyl Hexapeptide-8, offering advantages in automation, scalability, and purification efficiency 68. The standard SPPS protocol employs RINK AMIDE-AM resin as the solid support, which provides the C-terminal amide functionality upon final cleavage 8. The synthesis proceeds through sequential coupling of Fmoc-protected amino acids in reverse order: Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Met-OH, Fmoc-Glu(OtBu)-OH, and Fmoc-Glu(OtBu)-OH, where Pbf denotes 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl protecting group for arginine, Trt represents trityl protection for glutamine, and OtBu indicates tert-butyl ester protection for glutamic acid side chains 813.
A critical innovation in SPPS methodology involves the use of modified N-hydroxyphthalimide derivatives as condensing agents, specifically p-dimethylquinone-modified N-hydroxyphthalimide, which significantly enhances coupling efficiency compared to conventional activators 6. This condensing agent, used in combination with N,N'-diisopropylcarbodiimide (DIC), achieves near-quantitative coupling yields (>99%) for each amino acid incorporation step, thereby minimizing deletion sequences and improving final product purity 6. Typical coupling reactions proceed for 2-4 hours at room temperature (20-25°C) with 3-5 molar excess of activated amino acid relative to resin loading 6.
The Fmoc deprotection step utilizes 20-30% piperidine in dimethylformamide (DMF), with reaction times of 5-10 minutes repeated twice to ensure complete removal of the fluorenylmethyloxycarbonyl protecting group 8. Following the final amino acid coupling, N-terminal acetylation is accomplished using acetic anhydride (5-10 equivalents) in the presence of N,N-diisopropylethylamine (DIPEA) as base, typically requiring 30-60 minutes for completion 813.
The cleavage cocktail composition critically influences both yield and purity of the crude peptide. An optimized formulation consists of trifluoroacetic acid (TFA) 92.5%, triisopropylsilane (TIS) 2.5%, water 2.5%, and ethanedithiol (EDT) 2.5% by volume, where TIS and EDT function as carbocation and sulfur-protecting scavengers respectively, preventing side reactions during acidolytic cleavage 8. Cleavage proceeds for 2-3 hours at room temperature, followed by precipitation in cold diethyl ether (10-fold volume excess) to obtain crude peptide as a white precipitate 8.
An alternative liquid-phase approach offers advantages for large-scale production by reducing organic solvent consumption and simplifying purification 13. This convergent strategy involves initial synthesis of three dipeptide building blocks: Ac-Glu(OtBu)-Glu(OtBu)-OH, H-Met-Gln(Trt)-OH, and H-Arg(Pbf)-Arg(Pbf)-NH₂, followed by sequential coupling to form tetrapeptide and hexapeptide intermediates 13. The dipeptide syntheses employ solution-phase coupling with standard activating agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt), achieving isolated yields of 75-85% for each dipeptide unit 13.
The convergent assembly reduces the total number of coupling and deprotection cycles compared to linear SPPS, potentially improving overall yield for multi-gram scale production 13. However, this approach requires intermediate purification steps (typically by silica gel chromatography or recrystallization) that may offset the solvent savings, making it more suitable for production scales exceeding 100 g per batch 13.
Crude peptide purification universally employs reversed-phase high-performance liquid chromatography (RP-HPLC) using C18 stationary phases with gradient elution of water-acetonitrile containing 0.1% TFA 38. An innovative purification enhancement involves modified silica gel packing materials incorporating N-(benzo[d]thiazole-2-ylmethyl)acrylamide and methyl 2-acrylamido-2-methoxyacetate modifiers, which improve resolution of closely related peptide impurities and increase column efficiency from typical 8,000-10,000 to 15,000-18,000 theoretical plates per meter 8. This modification enables single-pass purification to achieve >98% purity as determined by analytical HPLC, compared to 95-96% purity obtained with conventional C18 columns requiring multiple purification cycles 8.
Quality control specifications for pharmaceutical-grade Acetyl Hexapeptide-8 include:
Advanced characterization employs isotope dilution mass spectrometry (IDMS) in combination with quantitative nuclear magnetic resonance (qNMR) for absolute purity determination traceable to SI units, achieving measurement uncertainties of ±0.3-0.5% (k=2) 15. This dual-method approach provides reference standard materials essential for regulatory compliance and inter-laboratory comparability 15.
Acetyl Hexapeptide-8 demonstrates amphiphilic character with pH-dependent solubility profiles. In aqueous systems, solubility reaches 50-500 g/L depending on pH and ionic strength, with maximum solubility observed at pH 5.5-6.5 where the peptide carries net positive charge facilitating electrostatic hydration 1113. The lyophilized powder form exhibits poor solubility in non-polar solvents and 1,2-pentanediol, limiting formulation options for oil-based cosmetics 4. However, specific crystalline polymorphs (Forms B, C, D, E) enable preparation of oil-soluble dispersions, with Form B achieving 2160 ppm concentration in 1,2-pentanediol and Forms C, D, E providing superior long-term stability in such matrices 410.
The peptide forms supramolecular complexes with L-carnitine malate ionic liquid at mass ratios of 5:1 to 500:1 (ionic liquid:peptide), creating biphasic systems where the peptide solution becomes encapsulated by the ionic liquid phase 1. These supramolecular assemblies exhibit reduced particle size (typically 50-200 nm by dynamic light scattering), improved dispersibility, and dual hydrophilic-lipophilic character that enhances transdermal delivery 1. The ionic liquid wrapping preserves peptide bioactivity while providing directional delivery to target sites, significantly improving bioavailability compared to free peptide 1.
Differential scanning calorimetry (DSC) analysis reveals that Acetyl Hexapeptide-8 polymorphs exhibit distinct thermal behaviors. Form D shows endothermic transitions at 248.8 ± 2°C and 255.5 ± 2°C, corresponding to crystal lattice rearrangement and melting respectively 10. Thermogravimetric analysis (TGA) indicates that the peptide remains thermally stable up to approximately 200°C under nitrogen atmosphere, with initial decomposition onset at 220-240°C depending on crystalline form and residual water content 410.
For long-term storage, the peptide requires maintenance at -20°C in sealed containers with desiccant to prevent moisture absorption and oxidative degradation 4. Under these conditions, solid peptide retains >95% purity for at least 24 months 4. Aqueous solutions demonstrate significantly reduced stability, with methionine oxidation proceeding at rates of 0.5-2.0% per month at 4°C and 2-8% per month at 25°C, depending on dissolved oxygen concentration and presence of metal ion contaminants 11. Addition of antioxidants such as sodium metabisulfite (0.01-0.05% w/v) or ethylenediaminetetraacetic acid (EDTA, 0.01-0.02% w/v) as metal chelator substantially reduces oxidation rates 1114.
The primary degradation pathway involves oxidation of the methionine residue to methionine sulfoxide (Met-SO) and subsequently to methionine sulfone (Met-SO₂), detectable by mass spectrometry as +16 Da and +32 Da mass shifts respectively 11. This oxidation is catalyzed by reactive oxygen species, transition metal ions (particularly Fe³⁺ and Cu²⁺), and exposure to light, especially UV wavelengths below 320 nm 11. Formulations must limit methionine oxidation-related peaks to ≤0.8% to maintain efficacy 11.
Secondary degradation mechanisms include:
Optimal stability is achieved in formulations maintained at pH 4.5-6.5, where deamidation and hydrolysis rates are minimized 511. Addition of citric acid to mobile phases or formulation buffers further improves stability and analytical reproducibility 3.
A highly sensitive detection method employs pre-column derivatization with amino-reactive fluorescent reagents prior to HPLC analysis 3. Two optimized derivatization reagents are (2,8-dimethyl-imidazo[1,2-a]pyridin-3-yl)-methanol and (6-(dimethoxymethyl)furano[3,2-b]pyridin-2-yl)-methanol, both activated by reaction with bis(trichloromethyl) carbonate (
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| INERTIA BIOTECHNOLOGY CO. LTD. | Anti-wrinkle and anti-aging cosmetic formulations requiring improved skin penetration, particularly for eye creams, serums, and facial treatments targeting dynamic wrinkles. | Supramolecular Acetyl Hexapeptide-8 | Enhanced bioavailability and transdermal absorption through L-carnitine malate ionic liquid encapsulation, achieving particle size reduction to 50-200 nm and dual hydrophilic-lipophilic properties for directional delivery. |
| SHENZHEN READLINE BIOTECHNOLOGY CO. LTD. | Oil-based cosmetic matrices including lipophilic serums, oil-soluble anti-aging products, and anhydrous formulations requiring stable peptide incorporation. | Acetyl Hexapeptide-8 Crystalline Forms (Form B, C, D, E) | Novel crystalline polymorphs enabling oil-soluble formulations with up to 2160 ppm concentration in 1,2-pentanediol, superior stability in lipophilic systems compared to lyophilized powder, with Form D exhibiting thermal transitions at 248.8±2°C and 255.5±2°C. |
| 浙江湃肽生物有限公司南京分公司 | Quality control and analytical testing laboratories for cosmetic raw materials, pharmaceutical-grade peptide verification, and regulatory compliance testing requiring precise quantification. | Pre-column Derivatization HPLC Detection System | Utilizes amino-derivative reagents from (2,8-dimethyl-imidazo[1,2-A]pyridin-3-yl)-methanol or (6-(dimethoxymethyl)furano[3,2-b]pyridin-2-yl)-methanol with bis(trichloromethyl) carbonate, achieving excellent detection sensitivity, accuracy and repeatability with citric acid mobile phase enhancement. |
| 陕西慧康生物科技有限责任公司 | Transparent anti-wrinkle cosmetic formulations including essences, eye creams, and facial serums requiring high peptide concentration with long-term stability and visible wrinkle reduction effects. | High-Content Transparent Acetyl Hexapeptide-8 Cosmetic | Contains 3.0%-15.0% acetyl hexapeptide-8 with fruit acid derivatives (1.0%-5.0%) improving solubility and stability at pH 4.5-6.5, demonstrating >50% protein content retention after six months and effective reduction of dynamic facial wrinkles. |
| 杭州梵琳科技有限公司 | Advanced anti-aging skincare products requiring enhanced transdermal delivery, particularly for deep wrinkle treatment and applications where maximum peptide bioavailability is critical. | Penetration-Enhanced Anti-Wrinkle Essence | Combines chemical penetration enhancers with liposome-encapsulated acetyl hexapeptide-8, significantly improving skin penetration and dermal distribution through reservoir-release mechanism. |